Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187948
Title: | Efficacy and safety of Intravitreal Aflibercept Vs Verteporfin Photodynamic Therapy in a Caucasian Population with Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial |
Author: | Silva, Rufino Arias, Luis Nunes, Sandrina Farinha, Claudia Coimbra, Rita Maques, João P. Cachulo, Maria L. Figueira, João Barreto, Patricia Madeira, Maria H. Pires, Isabel Sousa, João C. Distefano, Laura Rosa, Paulo Carneiro, Ângela Vaz Pereira, Sara Meireles, Angelina Cabrera, Francisco Bures, Anniken Mendonça, Luís Fernandez-Vega Sanz, Alvaro Barrão, Sandra Koh, Adrian Cheung, Chui Ming Gemmy Cunha Vaz, José G. Murta, Joaquim EVICR.net ATLANTIC Study Group |
Keywords: | Assaigs clínics Pòlips (Patologia) Malalties vasculars Clinical trials Polyps (Pathology) Vascular diseases |
Issue Date: | 13-Jul-2021 |
Publisher: | S. Karger AG |
Abstract: | Importance: Polypoidal choroidal vasculopathy (PCV) is far less common and studied in a Caucasian population than in an Asian population, and the optimal treatment approach remains to be confirmed. Methods: A 52-week, double-masked, sham-controlled, phase 4, investigator-initiated randomized clinical trial (RCT) in naive symptomatic Caucasian patients with PCV treated with aflibercept in a treat-and-extend regimen (T&E) (intravitreal aflibercept injection [IVAI] T&E). Patients were randomized at week 16 to receive IVAI T&E plus either sham photodynamic therapy (PDT) or standard fluence PDT with verteporfin. The main outcome measures were changes in best-corrected visual acuity (BCVA) from baseline to 52 weeks and polyp occlusion at week 52. Data are presented as median (interquartile range [IQR]) for BCVA, number of IVAI, and change in central retinal thickness (CRT). Results: Of the 50 patients included in the study, 48 patients completed the 52 weeks of follow-up. During this period, a significant median (IQR) BCVA gain of 6 [2-12] Early Treatment Diabetic Retinopathy Study letters was observed for all patients (p < 0.001), after 8 (7-9) injections, with a significant reduction of -93.0 [-154.0, -44.0] mu m in central macular thickness (p < 0.001). Using indocyanine green angiography, a complete occlusion of polypoidal lesions was documented in 72% of the cases. Still, no significant difference was detected between the sham PDT and the aflibercept PDT arms, at week 52, for BCVA change (6.5 [2-11] vs. 5 [2-13] letters (p = 0.98)), number of IVAIs (8.5 [7-9] vs. 8 [7-9] (p = 0.21)), change in CRT (-143 [-184; -47] vs. -89 [-123; -41.5] mu m [p = 0.23]), and rates of complete polyp occlusion: 77 versus 68% (p = 0.53) or presence of fluid: 68 versus 57% (p = 0.56). No serious ocular adverse events were registered in the 2 arms. Conclusions and Relevance: To our knowledge, this is the first RCT to compare aflibercept T&E monotherapy with aflibercept T&E plus verteporfin PDT in a Caucasian population with PCV. Aflibercept monotherapy in a T&E showed to be effective and safe with a significant median BCVA improvement of 6 letters and a complete occlusion of polypoidal lesions in near 3 quarters of the eyes, at 1 year. As only 22% of the eyes underwent PDT treatment, the benefit of combined treatment for PCV in Caucasian patients could not be definitively elucidated from this study. |
Note: | Reproducció del document publicat a: https://doi.org/10.1159/000518235 |
It is part of: | Ophthalmologica, 2022, vol. 245, num. 1, p. 80-90 |
URI: | http://hdl.handle.net/2445/187948 |
Related resource: | https://doi.org/10.1159/000518235 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
518235.pdf | 363.91 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License